Pay in 4 interest-free payments of $5.14 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Drug delivery partnership to advance next-generation oral therapies and help Novo Nordisk expand its obesity and diabetes portfolio
Retatrutide is an investigational GIP, GLP-1, and glucagon receptor triple agonist with no MHRA or EMA marketing authorisation
For CPT 99281, Cigna had the highest median negotiated rate at $675
Applicable Procedure Codes: C9399, J0180, J0217, J0218, J0219, J0221, J1203, J1322, J1458, J1743, J1809, J1931, J2508, J2840, J3397, J3490, J3590
Glucagon-like peptide 1-based therapies and risk of pancreatic cancer in patients with diabetes and obesity
Health Canada submissions typically follow FDA approval by several months
US$ 24.52
US$ 25.59
US$ 28.29
US$ 28.23
US$ 29.10
US$ 25.36
US$ 20.05
US$ 28.12
US$ 23.31
